| CD4+ CD28− T lymphocytes contribute to early atherosclerotic damage in rheumatoid arthritis patients R Gerli, G Schillaci, A Giordano, EB Bocci, O Bistoni, G Vaudo, ... Circulation 109 (22), 2744-2748, 2004 | 334 | 2004 |
| Defining disease activity states and clinically meaningful improvement in primary Sjögren's syndrome with EULAR primary Sjögren's syndrome disease activity (ESSDAI) and patient … R Seror, H Bootsma, A Saraux, SJ Bowman, E Theander, JG Brun, ... Annals of the rheumatic diseases 75 (2), 382-389, 2016 | 316 | 2016 |
| Validation of EULAR primary Sjögren's syndrome disease activity (ESSDAI) and patient indexes (ESSPRI) R Seror, E Theander, JG Brun, M Ramos-Casals, V Valim, T Dörner, ... Annals of the rheumatic diseases 74 (5), 859-866, 2015 | 303 | 2015 |
| Primary Sjögren’s syndrome as a multi-organ disease: impact of the serological profile on the clinical presentation of the disease in a large cohort of Italian patients C Baldini, P Pepe, L Quartuccio, R Priori, E Bartoloni, A Alunno, ... Rheumatology 53 (5), 839-844, 2014 | 280 | 2014 |
| COVID-19 as part of the hyperferritinemic syndromes: the role of iron depletion therapy C Perricone, E Bartoloni, R Bursi, G Cafaro, GM Guidelli, Y Shoenfeld, ... Immunologic research 68, 213-224, 2020 | 223 | 2020 |
| Balance between regulatory T and Th17 cells in systemic lupus erythematosus: the old and the new A Alunno, E Bartoloni, O Bistoni, G Nocentini, S Ronchetti, S Caterbi, ... Journal of Immunology Research 2012, 2012 | 192 | 2012 |
| Influence of geolocation and ethnicity on the phenotypic expression of primary Sjögren's syndrome at diagnosis in 8310 patients: a cross-sectional study from the Big Data … P Brito-Zerķn, N Acar-Denizli, M Zeher, A Rasmussen, R Seror, ... Annals of the rheumatic diseases 76 (6), 1042-1050, 2017 | 183 | 2017 |
| Precocious intima‐media thickening in patients with primary Sjögren's syndrome G Vaudo, EB Bocci, Y Shoenfeld, G Schillaci, R Wu, N Del Papa, C Vitali, ... Arthritis & Rheumatism 52 (12), 3890-3897, 2005 | 183 | 2005 |
| Clinical spectrum time course in anti Jo-1 positive antisynthetase syndrome: results from an international retrospective multicenter study L Cavagna, L Nuno, CA Scire, M Govoni, FJL Longo, F Franceschini, ... Medicine 94 (32), e1144, 2015 | 179 | 2015 |
| Cardiovascular disease risk burden in primary Sjögren's syndrome: results of a population‐based multicentre cohort study E Bartoloni, C Baldini, G Schillaci, L Quartuccio, R Priori, F Carubbi, V Bini, ... Journal of internal medicine 278 (2), 185-192, 2015 | 174 | 2015 |
| Biomarkers of lymphoma in Sjögren’s syndrome and evaluation of the lymphoma risk in prelymphomatous conditions: results of a multicenter study L Quartuccio, M Isola, C Baldini, R Priori, EB Bocci, F Carubbi, M Maset, ... Journal of autoimmunity 51, 75-80, 2014 | 174 | 2014 |
| How immunological profile drives clinical phenotype of primary Sjogren's syndrome at diagnosis: analysis of 10,500 patients (Sjogren Big Data Project) P Brito-Zerķn, N Acar-Denizli, WF Ng, M Zeher, A Rasmussen, T Mandl, ... Clinical and experimental rheumatology 36 (3), S102-S112, 2018 | 171 | 2018 |
| COVID-19: the new challenge for rheumatologists. F Ferro, E Elefante, C Baldini, E Bartoloni, I Puxeddu, R Talarico, ... Clinical and experimental rheumatology 38 (2), 175-180, 2020 | 167 | 2020 |
| Influence of antisynthetase antibodies specificities on antisynthetase syndrome clinical spectrum time course L Cavagna, E Trallero-Araguás, F Meloni, I Cavazzana, J Rojas-Serrano, ... Journal of clinical medicine 8 (11), 2013, 2019 | 164 | 2019 |
| The anti-viral facet of anti-rheumatic drugs: Lessons from COVID-19 C Perricone, P Triggianese, E Bartoloni, G Cafaro, AF Bonifacio, R Bursi, ... Journal of Autoimmunity 111, 102468, 2020 | 157 | 2020 |
| Association of anti-cyclic citrullinated peptide antibodies with subclinical atherosclerosis in patients with rheumatoid arthritis R Gerli, EB Bocci, Y Sherer, G Vaudo, S Moscatelli, Y Shoenfeld Annals of the rheumatic diseases 67 (5), 724-725, 2008 | 150 | 2008 |
| Altered immunoregulation in rheumatoid arthritis: the role of regulatory T cells and proinflammatory Th17 cells and therapeutic implications A Alunno, M Manetti, S Caterbi, L Ibba-Manneschi, O Bistoni, E Bartoloni, ... Mediators of inflammation 2015, 2015 | 148 | 2015 |
| Inflammatory and autoimmune mechanisms in the induction of atherosclerotic damage in systemic rheumatic diseases: two faces of the same coin E Bartoloni, Y Shoenfeld, R Gerli Arthritis care & research 63 (2), 178-183, 2011 | 135 | 2011 |
| International consensus: What else can we do to improve diagnosis and therapeutic strategies in patients affected by autoimmune rheumatic diseases (rheumatoid arthritis … R Giacomelli, A Afeltra, A Alunno, C Baldini, E Bartoloni-Bocci, ... Autoimmunity Reviews 16 (9), 911-924, 2017 | 133 | 2017 |
| Efficacy and safety of off-label use of rituximab in refractory lupus: data from the Italian Multicentre Registry L Iaccarino, E Bartoloni, L Carli, F Ceccarelli, F Conti, S De Vita, ... Clinical and experimental rheumatology 33 (4), 449-456, 2015 | 133 | 2015 |
